Skip to main content
. 2016 Mar 18;6:23241. doi: 10.1038/srep23241

Figure 5. Activation of the PI3K/Akt and MEK/ERK pathways by the extracellular fragment of GPNMB was blocked by NKA inhibitors.

Figure 5

NSC34 cells were treated with human recombinant GPNMB (2.5 μg/ml), and ouabain (10 μM) or sanguinarine (0.3 μM). (A) The level of phosphorylated Akt was quantified relative to total Akt. (B) The level of phosphorylated ERK1/2 was quantified relative to total ERK. Each column represents the mean ± S.E.M. (n = 3 or 4). *p < 0.05, **p < 0.01 vs. vehicle group (Tukey’s test). (C) The level of p-Src protein was examined at different time points (0–60 min) after incubating with the recombinant extracellular GPNMB (2.5 μg/ml). The level of phosphorylated Src was quantified relative to total Src. Statistical comparisons were made using Dunnett’s test (vs. control group). Each column and bar represents the mean ± S.E.M. (n = 4). n.s.: not significant.